College for Light Medicine and Photobiomodulation, D-82319 Starnberg, Germany.
Niraxx Light Therapeutics, Inc., Irvine, CA 92617, USA.
Biomolecules. 2020 Apr 15;10(4):610. doi: 10.3390/biom10040610.
Photobiomodulation (PBM) might be an effective treatment for Parkinson's disease (PD) in human patients. PBM of the brain uses red or near infrared light delivered from a laser or an LED at relatively low power densities, onto the head (or other body parts) to stimulate the brain and prevent degeneration of neurons. PD is a progressive neurodegenerative disease involving the loss of dopamine-producing neurons in the substantia nigra deep within the brain. PD is a movement disorder that also shows various other symptoms affecting the brain and other organs. Treatment involves dopamine replacement therapy or electrical deep brain stimulation. The present systematic review covers reports describing the use of PBM to treat laboratory animal models of PD, in an attempt to draw conclusions about the best choice of parameters and irradiation techniques. There have already been clinical trials of PBM reported in patients, and more are expected in the coming years. PBM is particularly attractive as it is a non-pharmacological treatment, without any major adverse effects (and very few minor ones).
光生物调节（PBM）可能是一种治疗人类帕金森病（PD）的有效方法。大脑的 PBM 使用从激光或 LED 发出的低功率密度的红光或近红外光，照射头部（或其他身体部位）以刺激大脑并防止神经元退化。PD 是一种进行性神经退行性疾病，涉及大脑深处黑质中产生多巴胺的神经元的丧失。PD 是一种运动障碍，还会出现影响大脑和其他器官的各种其他症状。治疗包括多巴胺替代疗法或深部脑电刺激。本系统评价涵盖了描述使用 PBM 治疗 PD 实验室动物模型的报告，试图就最佳参数和辐照技术选择得出结论。已经有报道称在患者中进行了 PBM 的临床试验，预计未来几年还会有更多的临床试验。PBM 特别有吸引力，因为它是一种非药物治疗方法，没有任何重大不良反应（只有极少数轻微不良反应）。
